Home » Business » Manufacturing
MSD eyes US$1.5b in R&D
By Ding Yining |
December 7, 2011, Wednesday
|
Print Edition
Print Edition
MERCK & Co yesterday announced the setting up of its Asia Research & Development headquarters in Beijing, which is part of the company's US$1.5 billion investment in pharmaceutical research and development in China over the next five years.
Located in Wangjing Science and Technology Park, the center under MSD China will be the firm's fourth global R&D facility after Switzerland, Germany and the United States.
Merck & Co is known as MSD outside the United States and Canada.
"Establishing MSD Asia R&D headquarters represents our strategy to succeed in fast-growing markets," said Peter S. Kim, president of Merck Research Laboratories.
The first phase of the 47,000-square-meter R&D facility may be operational in 2014 and will have 600 employees.
MSD also plans to expand clinical trials to get more new drugs approved by the State Food and Drug Administration as well as academic collaboration with Chinese institutions.
"We wish to use the R&D facility in Beijing as a platform to accelerate the listing of new drugs in China," Kim said.
Earlier this year, the drug maker partnered Simcere Pharmaceutical Group for a joint venture in China.
Located in Wangjing Science and Technology Park, the center under MSD China will be the firm's fourth global R&D facility after Switzerland, Germany and the United States.
Merck & Co is known as MSD outside the United States and Canada.
"Establishing MSD Asia R&D headquarters represents our strategy to succeed in fast-growing markets," said Peter S. Kim, president of Merck Research Laboratories.
The first phase of the 47,000-square-meter R&D facility may be operational in 2014 and will have 600 employees.
MSD also plans to expand clinical trials to get more new drugs approved by the State Food and Drug Administration as well as academic collaboration with Chinese institutions.
"We wish to use the R&D facility in Beijing as a platform to accelerate the listing of new drugs in China," Kim said.
Earlier this year, the drug maker partnered Simcere Pharmaceutical Group for a joint venture in China.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
